Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Precision Medicine for Parkinson's Disease: Ambroxol for Glucocerebrosidase-Associated Parkinson's Disease, First Trial Completed.

Movement disorders : official journal of the Movement Disorder Society - 1 Jul 2020

Schneider Susanne A, Alcalay Roy N

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glucosylceramidase
Share to Mutation
Share to Parkinson Disease
Share to Precision Medicine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32379375
DOI: 10.1002/mds.28072

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Precision Medicine for Parkinson's Disease: Ambroxol for Glucocerebrosidase-Associated Parkinson's Disease, First Trial Completed.PMID 32379375Read ↗

Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.Semantic proximity Read ↗

Precision medicine for disease modification in Parkinson diseaseSemantic proximity Read ↗

Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation.Semantic proximity Read ↗

[Progress in diagnosis and therapy for Parkinson's disease].Semantic proximity Read ↗

Promising disease-modifying therapies for Parkinson's disease.Semantic proximity Read ↗

Parkinson’s disease treatment: past, present, and futureSemantic proximity Read ↗

Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease.Semantic proximity Read ↗

Disease‑Modifying Therapies for Parkinson’s Disease: Biological Mechanisms, Pharmacological Strategies, and Clinical PipelineSemantic proximity Read ↗

LRRK2-targeted Parkinson disease drug advances into phase IIISemantic proximity Read ↗

Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.Semantic proximity Read ↗

[Treatments for Parkinson's Disease -Essential Knowledge for General Physicians - Topics: III. Recommended Usage of New Antiparkinson Drugs].Semantic proximity Read ↗

LRRK2 inhibitor progresses for Parkinson disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.